Damora Therapeutics, Inc. Stock Analysis & AI Score
Damora Therapeutics, Inc. (DMRA) has an ST Score of 47.0 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $50.00 price target (+146.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Damora Therapeutics, Inc. (DMRA) has an ST Score of 47.0 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $50.00 price target (+146.7% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthF
All factor grades
- Financial StrengthA+
- ForecastA
- ValuationC+
- ProfitabilityC-
- MomentumC-
- GrowthF
- Piotroski3/9
Contact
DMRA stock: frequently asked questions
What is DMRA's ST Score?
Damora Therapeutics, Inc. (DMRA) has an ST Score of 47.0 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is DMRA a buy, hold, or sell?
Analysts rate DMRA a Buy, with a price target of $50.00 (+146.7% vs the current price). Our ST Score grades it C+ (47.0/100). The ST Score is a data-driven signal, not a recommendation.
What are DMRA's factor grades?
Valuation C+, Profitability C-, Financial Strength A+, Momentum C-, Growth F, Forecast A.
What is DMRA's valuation grade?
Damora Therapeutics, Inc. (DMRA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is DMRA's growth grade?
Damora Therapeutics, Inc. (DMRA) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is DMRA's profitability grade?
Damora Therapeutics, Inc. (DMRA) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is DMRA's financial strength grade?
Damora Therapeutics, Inc. (DMRA) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for DMRA?
The average analyst price target for Damora Therapeutics, Inc. (DMRA) is $50.00 from 3 analysts, which is +146.7% versus the recent price of $20.27.
What is DMRA's Piotroski score?
Damora Therapeutics, Inc. (DMRA) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.